Capricor Therapeutics to Present Final Data from HOPE-2 Trial with CAP-1002 in Duchenne Muscular Dystrophy at World Muscle Society 2021
Stock Information for Capricor Therapeutics Inc.
Loading
Please wait while we load your information from QuoteMedia.